Cargando…
Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth
Anwulignan is a monomer compound derived from Schisandra sphenanthera lignans. It has been reported to possess a spectrum of pharmacological activities, including anti‐bacterial, anti‐inflammatory, anticancer and hepatoprotective properties. However, its anticancer capacity and molecular mechanism(s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933975/ https://www.ncbi.nlm.nih.gov/pubmed/33523587 http://dx.doi.org/10.1111/jcmm.16289 |
_version_ | 1783660731890139136 |
---|---|
author | Xie, Xiaomeng Wang, Xiangyu Shi, Xiaodan Zhang, Yuanyuan Laster, Kyle Vaughn Liu, Kangdong Dong, Zigang Kim, Dong Joon |
author_facet | Xie, Xiaomeng Wang, Xiangyu Shi, Xiaodan Zhang, Yuanyuan Laster, Kyle Vaughn Liu, Kangdong Dong, Zigang Kim, Dong Joon |
author_sort | Xie, Xiaomeng |
collection | PubMed |
description | Anwulignan is a monomer compound derived from Schisandra sphenanthera lignans. It has been reported to possess a spectrum of pharmacological activities, including anti‐bacterial, anti‐inflammatory, anticancer and hepatoprotective properties. However, its anticancer capacity and molecular mechanism(s) against non‐small cell lung cancer (NSCLC) have not been fully elucidated. Anwulignan significantly inhibited cell growth and increased G1‐phase cell cycle arrest in NSCLC cells. Anwulignan strongly attenuates the JAK1/STAT3 signalling pathway by directly targeting JAK1 protein kinase activity in vitro. The anticancer activity by Anwulignan is dependent upon the JAK1 protein expression. Remarkably, Anwulignan strongly inhibited tumour growth in vivo. In conclusion, Anwulignan is a novel JAK1 inhibitor that may have therapeutic implications for NSCLC management. |
format | Online Article Text |
id | pubmed-7933975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79339752021-03-15 Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth Xie, Xiaomeng Wang, Xiangyu Shi, Xiaodan Zhang, Yuanyuan Laster, Kyle Vaughn Liu, Kangdong Dong, Zigang Kim, Dong Joon J Cell Mol Med Original Articles Anwulignan is a monomer compound derived from Schisandra sphenanthera lignans. It has been reported to possess a spectrum of pharmacological activities, including anti‐bacterial, anti‐inflammatory, anticancer and hepatoprotective properties. However, its anticancer capacity and molecular mechanism(s) against non‐small cell lung cancer (NSCLC) have not been fully elucidated. Anwulignan significantly inhibited cell growth and increased G1‐phase cell cycle arrest in NSCLC cells. Anwulignan strongly attenuates the JAK1/STAT3 signalling pathway by directly targeting JAK1 protein kinase activity in vitro. The anticancer activity by Anwulignan is dependent upon the JAK1 protein expression. Remarkably, Anwulignan strongly inhibited tumour growth in vivo. In conclusion, Anwulignan is a novel JAK1 inhibitor that may have therapeutic implications for NSCLC management. John Wiley and Sons Inc. 2021-02-01 2021-03 /pmc/articles/PMC7933975/ /pubmed/33523587 http://dx.doi.org/10.1111/jcmm.16289 Text en © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Xie, Xiaomeng Wang, Xiangyu Shi, Xiaodan Zhang, Yuanyuan Laster, Kyle Vaughn Liu, Kangdong Dong, Zigang Kim, Dong Joon Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth |
title | Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth |
title_full | Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth |
title_fullStr | Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth |
title_full_unstemmed | Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth |
title_short | Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth |
title_sort | anwulignan is a novel jak1 inhibitor that suppresses non‐small cell lung cancer growth |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933975/ https://www.ncbi.nlm.nih.gov/pubmed/33523587 http://dx.doi.org/10.1111/jcmm.16289 |
work_keys_str_mv | AT xiexiaomeng anwulignanisanoveljak1inhibitorthatsuppressesnonsmallcelllungcancergrowth AT wangxiangyu anwulignanisanoveljak1inhibitorthatsuppressesnonsmallcelllungcancergrowth AT shixiaodan anwulignanisanoveljak1inhibitorthatsuppressesnonsmallcelllungcancergrowth AT zhangyuanyuan anwulignanisanoveljak1inhibitorthatsuppressesnonsmallcelllungcancergrowth AT lasterkylevaughn anwulignanisanoveljak1inhibitorthatsuppressesnonsmallcelllungcancergrowth AT liukangdong anwulignanisanoveljak1inhibitorthatsuppressesnonsmallcelllungcancergrowth AT dongzigang anwulignanisanoveljak1inhibitorthatsuppressesnonsmallcelllungcancergrowth AT kimdongjoon anwulignanisanoveljak1inhibitorthatsuppressesnonsmallcelllungcancergrowth |